| __timestamp | Ligand Pharmaceuticals Incorporated | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 59644696 |
| Thursday, January 1, 2015 | 24378000 | 79541000 |
| Friday, January 1, 2016 | 26621000 | 98015000 |
| Sunday, January 1, 2017 | 28653000 | 103958000 |
| Monday, January 1, 2018 | 37734000 | 103654000 |
| Tuesday, January 1, 2019 | 41884000 | 128951000 |
| Wednesday, January 1, 2020 | 64435000 | 135799000 |
| Friday, January 1, 2021 | 57483000 | 149883000 |
| Saturday, January 1, 2022 | 70062000 | 220206000 |
| Sunday, January 1, 2023 | 52790000 | 265542000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for sustaining growth and innovation. Ligand Pharmaceuticals Incorporated and Travere Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.
Ligand Pharmaceuticals started with a modest SG&A expense, which grew by approximately 133% over the decade, peaking in 2022. This reflects their strategic investments in expanding operations and enhancing market presence. In contrast, Travere Therapeutics exhibited a more aggressive increase, with expenses surging by over 345% during the same period, indicating a robust expansion strategy.
The year 2023 marked a significant divergence, with Travere's expenses reaching nearly five times that of Ligand's. This disparity highlights differing business models and growth strategies, offering valuable insights into the financial dynamics of the biotech sector.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.